Mark A. Pattoli

1.5k citations

14 papers · 891 indexed · h-index 10

Co-authors: James R. Burke Kim W. McIntyre Yuping Qiu F. Christopher Zusi John F. MacMaster Kurt R. Gregor Patrick Brassil Wendy Clarke
Topics: NF-κB Signaling Pathways (6 papers)Galectins and Cancer Biology (3 papers)Chronic Lymphocytic Leukemia Research (3 papers)
Cited by: Cancer Research Immunology Toxicology
Journals: Journal of Biological Chemistry PLoS ONE Analytical Chemistry
Partner nations: United States Germany India

In The Last Decade

Mark A. Pattoli

14 papers receiving 868 citations

Peers

Countries citing papers authored by Mark A. Pattoli

Since Specialization

Citations

This map shows the geographic impact of Mark A. Pattoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Pattoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Pattoli more than expected).

Fields of papers citing papers by Mark A. Pattoli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Pattoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Pattoli. The network helps show where Mark A. Pattoli may publish in the future.

Co-authorship network of co-authors of Mark A. Pattoli

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Pattoli. A scholar is included among the top collaborators of Mark A. Pattoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Pattoli. Mark A. Pattoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton’s Tyrosine Kinase 2019 ·SLAS DISCOVERY ·(unknown),James D. Vasta,(unknown),Gregory Locke,(unknown),Mark A. Pattoli,Stacey Skala,James R. Burke,Scott H. Watterson,Joseph A. Tino,Poncho Meisenheimer,Brian J. Arey,Jonathan Lippy,(unknown),Matthew B. Robers,Andrew J. Tebben,Charu Chaudhry	9
2	Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS 2019 ·Analytical Chemistry ·Naiyu Zheng,Ian M. Catlett,Kristin Taylor,Huidong Gu,Mark A. Pattoli,Robert Neely,Wenying Li,Alban J. Allentoff,Xiling Yuan,Eugene Ciccimaro,Ming Yao,Bethanne M. Warrack,James R. Burke,Yan J Zhang,Renuka Pillutla,Jianing Zeng	9
3	Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series 2018 ·Bioorganic & Medicinal Chemistry Letters ·Qingjie Liu,Douglas G. Batt,Charu Chaudhry,Jonathan Lippy,Mark A. Pattoli,(unknown),(unknown),Percy H. Carter,James R. Burke,Joseph A. Tino	12
4	Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care 2017 ·PLoS ONE ·Kathleen M. Gillooly,Claudine Pulicicchio,Mark A. Pattoli,Lihong Cheng,Stacey Skala,Elizabeth Heimrich,Kim W. McIntyre,Tracy Taylor,Daniel Kukral,Shailesh Dudhgaonkar,(unknown),Dana Banas,Scott H. Watterson,Joseph A. Tino,Aberra Fura,James R. Burke	47
5	Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: Synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis 2010 ·Bioorganic & Medicinal Chemistry Letters ·Alaric J. Dyckman,Charles M. Langevine,Claude Quesnelle,James Kempson,Junqing Guo,Patrice Gill,Steven H. Spergel,Scott H. Watterson,Tianle Li,David S. Nirschl,Kathleen M. Gillooly,Mark A. Pattoli,Kim W. McIntyre,(unknown),Murray McKinnon,John H. Dodd,Joel C. Barrish,James R. Burke,William J. Pitts	7
6	Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IκB kinase 2009 ·Bioorganic & Medicinal Chemistry Letters ·James Kempson,Junqing Guo,Jagabandhu Das,Robert V. Moquin,Steven H. Spergel,Scott H. Watterson,Charles M. Langevine,Alaric J. Dyckman,Mark A. Pattoli,James R. Burke,Xiao-Xia Yang,Kathleen M. Gillooly,Kim W. McIntyre,(unknown),John H. Dodd,Murray McKinnon,Joel C. Barrish,William J. Pitts	16
7	Synthesis and structure–activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-β inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Makonen Belema,Amy Bunker,Van N. Nguyen,Françis Beaulieu,Carl Ouellet,Yuping Qiu,Yunhui Zhang,Alain Martel,James R. Burke,Kim W. McIntyre,Mark A. Pattoli,(unknown),Kathleen M. Gillooly,Wendy Clarke,Patrick Brassil,(unknown),Dolatrai M. Vyas	26
8	Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·Françis Beaulieu,Carl Ouellet,Edward H. Ruediger,Makonen Belema,Yuping Qiu,Xuejie Yang,Jacques Banville,James R. Burke,Kurt R. Gregor,John F. MacMaster,Alain Martel,Kim W. McIntyre,Mark A. Pattoli,F. Christopher Zusi,Dolatrai M. Vyas	45
9	Collagen and Aggrecan Degradation Is Blocked in Interleukin-1-Treated Cartilage Explants by an Inhibitor of IκB Kinase through Suppression of Metalloproteinase Expression 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Mark A. Pattoli,John F. MacMaster,Kurt R. Gregor,James R. Burke	47
10	BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice 2003 ·Journal of Biological Chemistry ·James R. Burke,Mark A. Pattoli,Kurt R. Gregor,Patrick Brassil,John F. MacMaster,Kim W. McIntyre,Xiaoxia Yang,(unknown),Wendy Clarke,Joann Strnad,Yuping Qiu,F. Christopher Zusi	439
11	A highly selective inhibitor of IκB kinase, BMS‐345541, blocks both joint inflammation and destruction in collagen‐induced arthritis in mice 2003 ·Arthritis & Rheumatism ·Kim W. McIntyre,David J. Shuster,Kathleen M. Gillooly,Donna M. Dambach,Mark A. Pattoli,(unknown),Xiadi Zhou,Yuping Qiu,F. Christopher Zusi,James R. Burke	185
12	Gangliosides of monocyte-derived macrophages of adults with advanced HIV infection show reduced surface accessibility 1998 ·Journal of Leukocyte Biology ·Charles S. Berenson,Melissa Gallery,Manpreet S. Katari,(unknown),Mark A. Pattoli	5
13	Specific binding of Haemophilus influenzae to minor gangliosides of human respiratory epithelial cells 1997 ·Infection and Immunity ·Mohamad G. Fakih,Timothy F. Murphy,Mark A. Pattoli,Charles S. Berenson	32
14	A monoclonal antibody to human macrophage gangliosides inhibits macrophage migration 1996 ·Journal of Leukocyte Biology ·Charles S. Berenson,(unknown),Mark A. Pattoli,Timothy F. Murphy	12

About Mark A. Pattoli

Mark A. Pattoli is a scholar working on Toxicology, Cancer Research and Immunology, having authored 14 papers that have together received 891 indexed citations. Recurring topics across this work include NF-κB Signaling Pathways (6 papers), Galectins and Cancer Biology (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Cancer Research (368 citations), Immunology (296 citations) and Toxicology (29 citations). Mark A. Pattoli has collaborated with scholars based in United States, Germany and India. Frequent co-authors include James R. Burke, Kim W. McIntyre, Yuping Qiu, F. Christopher Zusi, John F. MacMaster, Kurt R. Gregor, Patrick Brassil, Wendy Clarke, Xiaoxia Yang and Joann Strnad. Their work appears in journals such as Journal of Biological Chemistry, PLoS ONE and Analytical Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact